Comparative study of the value of dual tracer PET/CT in evaluating breast cancer.

The present study was conducted to assess the relationship between tumor uptake and pathologic findings using dual-tracer PET/computed tomography (CT) in patients with breast cancer. Seventy-four patients with breast cancer (mean age 54 years) who underwent (11)C-choline and 2-[(18)F]fluoro-2-deoxy-d-glucose ((18)F-FDG) PET/CT prior to surgery on the same day were enrolled in the present study. Images were reviewed by a board-certified radiologist and two nuclear medicine specialists who were unaware of any clinical information and a consensus was reached. Uptake patterns and measurements of dual tracers were compared with the pathologic findings of resected specimens as the reference standard. Mean (±SD) tumor size was 5.9 ± 3.2 cm. All primary tumors were identified on (18)F-FDG PET/CT and (11)C-choline PET/CT. However, (18)F-FDG PET/CT demonstrated focal uptake of the primary tumor with (n = 38; 51%) or without (n = 36; 49%) diffuse background breast uptake. Of the pathologic findings, multiple logistic regression analysis revealed an independent association between fibrocystic change and diffuse background breast uptake (odds ratio [OR] 8.57; 95% confidence interval [CI] 2.86-25.66; P < 0.0001). Tumors with higher histologic grade, nuclear grade, structural grade, nuclear atypia, and mitosis had significantly higher maximum standardized uptake values (SUV(max)) and tumor-to-background ratios (TBR) for both tracers. Multiple logistic regression analysis revealed that only the degree of mitosis was independently associated with a high SUV(max) (OR 7.45; 95%CI 2.21-25.11; P = 0.001) and a high TBR (OR 5.41; 95%CI 1.13-25.96; P = 0.035) of (11)C-choline PET/CT. In conclusion, (11)C-choline may improve tumor delineation and reflect tumor aggressiveness on PET/CT in patients with breast cancer.

Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report.

OBJECTIVE: (18)F-2-deoxy-2-fluoro-D-glucose positron emission tomography (FDG-PET) is a promising screening modality targeting whole body. However, the validity of PET cancer screening remains to be assessed. Even the screening accuracy for whole-body screening using FDG-PET has not been evaluated. In this study, we investigated the screening accuracy of PET cancer screening. METHODS: A total of 2911 asymptomatic participants (1629 men and 1282 women, mean age 59.79 years) underwent both FDG-PET and other thorough examinations for multiple organs (gastrofiberscopy, total colonofiberscopy or barium enema, low-dose thin section computed tomography and sputum cytology, abdominal ultrasonography, an assay of prostate-specific antigen, mammography, mammary ultrasonography, Pap smear for the uterine cervix, and magnetic resonance imaging for the endometrium and ovaries) between February 2004 and January 2005, and followed sufficiently. The detection rate, sensitivity, specificity, and positive predictive value of FDG-PET were calculated using cancer data obtained from all examinations along with a 1 year follow-up. RESULTS: From among 2911 participants FDG-PET found 28 cancers, 129 cancers were PET negative. PET-positive cancers comprised seven colorectal cancers, four lung cancers, four thyroid cancers, three breast cancers, two gastric cancers, two prostate cancers, two small intestinal sarcomas (gastrointestinal stromal tumors), one malignant lymphoma, one head and neck malignancy (nasopharyngeal carcinoid tumor), one thymoma, and one hepatocellular carcinoma. PET-negative cancers included 22 gastric cancers and 20 prostate cancers that were essentially difficult to detect using FDG-PET. The overall detection rate, sensitivity, specificity, and positive predictive value were estimated to be 0.96%, 17.83%, 95.15%, and 11.20%, respectively. CONCLUSIONS: FDG-PET can detect a variety of cancers at an early stage as part of a whole-body screening modality. The detection rate of PET cancer screening was higher than that of other screening modalities, which had already shown evidence of efficacy. However, the sensitivity of PET cancer screening was lower than that of other thorough examinations performed at our institute. FDG-PET has some limitations, and cancer screening using only FDG-PET is likely to miss some cancers.

[Risk-benefit analysis of 18FDG PET cancer screening].

The benefits of (18)F-fluorodeoxyglucose ((18)FDG) positron emission tomography (PET) cancer screening are expected to include a large population of examinees and are intended for a healthy group. Therefore, we attempted to determine the benefit/risk ratio, estimated risk of radiation exposure, and benefit of cancer detection. We used software that embodied the method of the International Commission on Radiological Protection (ICRP) to calculate the average duration of life of radiation exposure. We calculated the lifesaving person years of benefit to be obtained by (18)FDG PET cancer screening detection. We also calculated the benefit/risk ratio using life-shortening and lifesaving person years. According to age, the benefit/risk ratio was more than 1 at 35-39 years old for males and 30-34 years old for females. (18)FDG PET cancer screening also is effective for examinees older than this. A risk-benefit analysis of (18)FDG-PET/computed tomography (CT) cancer screening will be necessary in the future.

Estimation of radioactivity in single-photon emission computed tomography for sentinel lymph node biopsy in a torso phantom study.

OBJECTIVE: The number of lymph nodes to be removed is determined from residual counts. Advance estimation of residual radioactivity in lymphatic nodes before a biopsy is useful for reducing surgical operation time. The purpose of this study was to estimate the total radioactivity of a small hotspot in single-photon emission computed tomography (SPECT) of a torso phantom. METHODS: A cross-calibration study was performed to convert counts in SPECT images to radioactivity. A simulation study was performed to estimate the size of the volume of interest (VOI) covering a hotspot corrupted with full-width at half-maximum between 8 and 16 mm. The estimation of total radioactivity was validated in a torso phantom study using small sources. RESULTS: True radioactivity was approximately equal to integrated values of hotspots using the VOI with a diameter of 40 mm in our simulation study. The difference was less than 18% in cases of more than 9.4 kBq. CONCLUSION: The total radioactivity in small sources simulating a typical sentinel node was estimated from SPECT images using a VOI of 40 mm in a torso phantom study. Because the difference from actual values was less than 10% on average when radioactivities were more than 9.4 kBq, the total radioactivity of a lymph node can be estimated in a clinical examination.

Detection of lung cancer by FDG-PET cancer screening program: a nationwide Japanese survey.

AIM: The aim of this study was to analyze the lung cancer detection rate in asymptomatic individuals by the Fluorine-18 fluorodeoxyglucose-positron emission tomography FDG-PET cancer screening program in Japan. MATERIALS AND METHODS: A total of 153,775 asymptomatic individuals underwent the FDG-PET cancer screening program; the 854 cases with findings that indicated suspected lung cancer by any detection method were analyzed. RESULTS: Among the 854 cases, 319 were verified as lung cancer. The relative sensitivity and positive predictive value (PPV) of FDG-PET were 86.5% and 38.9% for lung cancer, respectively. The sensitivity of PET/computed tomography (CT) scanner was higher than that of dedicated PET (100.0% vs. 63.2%), indicating that CT imaging was effective for lung cancer screening. The majority of lung carcinomas detected by FDG-PET screening were UICC stage IA or IB, but detection of smaller or less invasive carcinomas was limited. CONCLUSION: The FDG-PET screening program in Japan detected lung cancer at an early stage.

The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006-2009) nationwide survey.

OBJECTIVE: The aim of this study was to survey the 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) cancer screening program conducted in Japan. METHODS: The "FDG-PET cancer screening program" included both FDG-PET and positron emission tomography with computed tomography (PET/CT) with or without other combined screening tests that were performed for cancer screening in asymptomatic subjects. A total of 155,456 subjects who underwent the FDG-PET cancer screening program during 2006-2009 were analyzed. RESULTS: Of the 155,456 subjects, positive findings suggesting possible cancer were noted in 16,955 (10.9 %). The number of cases with detected cancer was 1,912 (1.23 % of the total screened cases, annual range 1.14-1.30 %). Of the 1,912 cases of detected cancer, positive findings on FDG-PET were present in 1,491 cases (0.96 % of the total number of screened cases). According to the results of further examinations, the true positive rate for subjects with suggested possible cancer (positive predictive value) was 32.3 % with FDG-PET. Cancers of the colon/rectum, thyroid, lung, and breast were most frequently found (396, 353, 319, and 163 cases, respectively) with high PET sensitivity (85.9, 90.7, 86.8, 84.0 %, respectively). Prostate cancer and gastric cancer (165 and 124 cases, respectively) had low PET sensitivity (37.0 and 37.9 %, respectively). The Union for International Cancer Control (UICC) clinical stage of cancer found with the FDG-PET cancer screening program was mainly Stage I. CONCLUSIONS: The FDG-PET screening program in Japan has detected a variety of cancers at an early stage. However, several cancers were found in repeated FDG-PET cancer screening program, indicating the limitation of a one-time FDG-PET cancer screening program. The value of the FDG-PET cancer screening program is left to the judgment of individuals with regard to its potentials and limitations.

[Optimization of the scan time is based on the physical index in FDG-PET/CT].

PURPOSE: The image quality of Positron Emission Tomography (PET) using (18)F-fluoro-2-deoxy-D-glucose is extremely important to diagnose cancer precisely. The purpose of this study is to inspect the physical indexes that are correlated with image quality and optimization of the scan time, utilizing the physical index. METHODS: This study calculated two kinds of patient noise equivalent counts (NEC(patient) and NEC(density)) and signal to noise ratio in liver (SNR(liver)) to measure PET image quality. We estimated the correlation coefficient between the visual assessment of PET image quality and physical indexes to assess the degree of correlation. We also set the optimal scan time, depending on body mass index (BMI), using the physical index and examined the efficacy of the optimization. RESULTS: NEC(density) showed the highest correlation coefficient in PET image quality (r=0.743, p<0.001). By optimizing the scan time using NEC(density), we showed there was no correlation between BMI and NEC(density) (r=0.192, p=0.047). In addition, reduced dependence of the PET image quality by BMI was showed. CONCLUSION: The optimization of the scan time using NEC(density) reduces deterioration of the PET image quality by patient habitus.

Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey.

OBJECTIVE: The most distinctive feature of FDG-PET cancer screening program is the ability to find various kinds of malignant neoplasms in a single test. The aim of this survey is to clarify the range and frequency of various malignant neoplasms detected by FDG-PET cancer screening performed in Japan. METHODS: "FDG-PET cancer screening" was defined as FDG-PET or positron emission tomography and computed tomography (PET/CT) scan with or without other tests performed for cancer screening of healthy subjects. This survey was based on a questionnaire regarding FDG-PET cancer screening. We analyzed the situation of 9 less frequently found malignant neoplasms including malignant lymphoma, malignancy of head and neck, esophagus, hepatobiliary and gallbladder, pancreas, kidney, cervical and uterine, ovary, and bladder. RESULTS: The detailed information of subjects with the suspected 9 kinds of malignant neoplasms mentioned above in the FDG-PET cancer screening program was studied in a total of 1,219 cases from 212 facilities. A statistical significance between PET/CT and PET was found in relative sensitivity and PPV for renal cell cancer. Malignant lymphoma was frequently of indolent type, suspected head and neck cancers had many false-positive results, and pancreatic cancer detected in this program was often in the advanced stage even in asymptomatic subjects. The recommendation of combined screening modality to PET or PET/CT was as follows: gastric endoscopy for assessing early esophageal cancer; abdominal ultrasound for screening hepatobiliary and gallbladder cancer; pelvic magnetic resonance imaging for assessing gynecological and pelvic cancers; and the CA125 blood test for screening ovarian cancer. Delayed image was helpful depending on the type of suspected malignant neoplasm. CONCLUSION: We analyzed various types of malignant neoplasms detected by the FDG-PET cancer screening program and presented recommended combination of examinations to cover FDG-PET and PET/CT.

Radiation exposure and risk-benefit analysis in cancer screening using FDG-PET: results of a Japanese nationwide survey.

OBJECTIVE: The aim of this study was to estimate radiation exposure and evaluate the risks and benefits of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in cancer screening. METHODS: A nationwide survey of FDG-PET cancer screening was conducted in 2006, and the results were analyzed with a common index, "extension/shortening of the average life expectancy." RESULTS: The average estimated effective dose was 4.4 mSv (male 4.7 mSv; female 4.0 mSv) for dedicated PET and 13.5 mSv (male 14.2 mSv; female 12.8 mSv) for PET/computed tomography (CT). The risk-benefit break-even age from the viewpoint of radiation exposure was in the 40s for men and 30s for women for dedicated PET and in the 50s for men and 50s (variable injection dose) or 60s (constant injection dose) for women for PET/CT. CONCLUSIONS: FDG-PET cancer screening is beneficial for examinees above the break-even ages. The risks and benefits should be explained to examinees because of the larger radiation used in cancer FDG-PET screening compared with other X-ray tests.

Multi-bed-position acquisition technique for deep inspiration breath-hold PET/CT: a preliminary result for pulmonary lesions.

OBJECTIVE: The deep inspiration breath-hold (DIBH) technique for positron emission tomography/computed tomography (PET/CT) is under investigation for its contribution to the accurate diagnosis of pulmonary lesions. "Step and shoot" or multi-bed-position image acquisition is necessary to improve the accuracy of whole-lung evaluation. The purpose of this study was to describe the method and preliminary results of evaluating pulmonary lesions using multi-bed-position deep inspiration breath-hold (MDIBH) PET/CT. METHODS: Thirteen patients with a total of 32 metastatic pulmonary lesions underwent both whole-body free-breath (FB) and whole-lung MDIBH-PET/CT sessions with suitable axial slice overlap. The self-breath holding technique was used for reproducibility of the DIBH condition. The standard FB-PET/CT was performed under the FB condition, which was followed by the MDIBH-PET/CT performed under the DIBH condition. Accuracy of alignment between CT and PET images and CT image quality were evaluated independently on dependent density, motion artifact, and heterogeneity attenuation. Mean standardized uptake value (SUV) in normal lung [Background (BG)-SUV(mean)], maximum SUV (SUV(max)) of lesion (lesion-SUV(max)), tumor background ratios (TBRs), and uptake volumes (UVs) were evaluated quantitatively. RESULTS: Improvements in artifacts were statistically significant using MDIBH-PET/CT. Improvements in alignment were statistically significant with the MDIBH-PET/CT for the diaphragm, heart and lung apices. CT image quality was statistically significantly higher with the MDIBH-PET/CT than with the FB-PET/CT in all indices. The decreases in BG-SUV(mean) were statistically significant (in all patients) with an average of -37%. Lesion-SUV(max) was increased in 7 of 32 (22%) lesions although average lesion-SUV(max) showed no statistical difference between the FB- and the MDIBH-PET/CT images. The increase in TBRs was statistically significant in 31 of 32 lesions (97%) in the MDIBH-PET/CT with an average of 57%. UVs were lower in 23 of 32 lesions (72%) in the MDIBH-PET/CT by -12% on average, although no statistical difference was confirmed between the techniques. CONCLUSIONS: The MDIBH-PET/CT can provide better-aligned fused images, featuring superior image quality, in both PET and CT images. The PET images showed low BG, non-blurring and high TBRs, and the CT images provided diagnostic capability of detecting small pulmonary lesions with negligible radiation exposure.

Evaluation of the risk of radiation exposure from new 18FDG PET/CT plans versus conventional X-ray plans in patients with pediatric cancers.

OBJECTIVE: Unnecessary radiological examination should be avoided, particularly for children, who are more vulnerable to radiation than adults. Replacement of X-ray examination with 18F-fluoro-2-deoxy-D-glucose (18FDG) positron emission tomography/computed tomography (PET/CT) is a potential option for reduction of radiation exposure, and thus improvement in the quality of life (QOL) of patients. Therefore, this study aimed to evaluate new plans integrating 18FDG PET/CT versus current conventional imaging (CI) plans for patients with pediatric cancers. The effects of radiation exposure from the two kinds of plans were compared using shortening of the average life expectancy as an index, and the related findings and effects of radiation exposure are discussed. METHODS: Effective radiation doses from CT scanning were calculated using the ImPACT CT Patient Dosimetry Calculator software. Radiation doses in different organs and tissues from radiopharmaceuticals were obtained from the International Commission on Radiological Protection (ICRP) publication 80. Shortening of average life expectancy was calculated using software in which the linear non-threshold model (LNT) by the ICRP was adopted. RESULTS: In current CI plans, the mean effective dose was 168.8 mSv (range 50.5-513.4 mSv) for males and 127 mSv (range 54-239.7 mSv) for females. The mean shortening of average life expectancy was 177 days (range 53.3-542 days) for males and 185 days (range 80.4-371 days) for females. In new plans, the mean effective dose was 64.1 mSv (range 54.1-84.5 mSv) for males and 68.2 mSv (range 58.1-88.0 mSv) for females. The mean shortening of life expectancy was 67.6 days (range 57.1-89.2 days) for males and 102.5 days (range 86.8-132.6 days) for females. CONCLUSIONS: New 18FDG PET/CT plans may relieve the patient's physical burden and contribute to improvement of the patient's QOL. These plans may also reduce medical costs because the number of examinations to be performed is reduced. Although deterministic effects are not observed in the CI plan, careful attention should be paid to other potential effects. Because the effective dose resulting from this plan is over 100 mSv, at which stochastic effects are known to occur, radiation-induced cancers may be expected.

A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor.

PURPOSE: The aim of this study was to assess the diagnostic performance of (18)F-Fluoride positron emission tomography (PET) or positron emission tomography/computed tomography (PET/CT) compared with bone scintigraphy (BS) planar or BS planar and single photon emission computed tomography (SPECT) in evaluating patients with metastatic bone tumor. MATERIALS AND METHODS: We performed a meta-analysis of all available studies addressing the diagnostic accuracy of (18)F-Fluoride PET, (18)F-Fluoride PET/CT, BS planar, and BS planar and SPECT for detecting the metastatic bone tumor. We determined sensitivities and specificities across studies, calculated positive and negative likelihood ratios, and drew summary receiver operating characteristic curves using hierarchical regression models. We also compared the effective dose and cost-effectiveness estimated by data from the enrolled studies between (18)F-Fluoride PET or PET/CT and BS planar or BS planar and SPECT. RESULTS: When comparing all studies with data on (18)F-Fluoride PET or PET/CT, sensitivity and specificity were 96.2% [95% confidence interval (CI) 93.5-98.9%] and 98.5% (95% CI 97.0-100%), respectively, on a patient basis and 96.9% (95% CI 95.9-98.0%) and 98.0% (95% CI 97.1-98.9%), respectively, on a lesion basis. The Az values of (18)F-Fluoride PET or PET/CT were 0.986 for the patient basis and 0.905 for the lesion basis, whereas those of BS or BS and SPECT were 0.866 for the patient basis and 0.854 for the lesion basis. However, the estimated effective dose and average cost-effective ratio were poorer for (18)F-Fluoride PET or PET/CT than those of BS planar or BS planar and SPECT. CONCLUSION: (18)F-Fluoride PET or PET/CT has excellent diagnostic performance for the detection of metastatic bone tumor, but the estimated effective dose and average cost-effective ratio are at a disadvantage compared with BS planar or BS planar and SPECT.